Original_edited.jpg

From innovation to therapeutic care
Go faster for Sickle Cell Disease patients

GR.jpg

INNOVHEM

A based-Genopole company founded on breakthrough innovation, 

INNOVHEM is developing solutions that will both promote the development and optimization of use of treatments for the most common genetic disease over the world, sickle cell disease.

famille_edited.jpg

Our Mission

Transform clinical care to improve patients quality of life

Our proposition

Combining innovative biomarkers with AI

Combining biomarkers adapted to Red Blood Cell diseases with AI, 

INNOVHEM is developping solutions, which make possible to optimize the care of patients: 

  • Improving the development of effective treatments

  • Offering personalized therapy for each patients

The Biomarkers

the method fbycell.png

 Fetal Hemoglobin per Red Blood Cell

- Related to the pathophysilogy of Sickle Cell Disease
- Accurate

The hemolysis.png

A new method to dose intra-vascular hemolysis

- Direct

- Accurate

The Team

A leadership on Sickle Cell Disease

Famille_%C3%A0_Antony_Sept_edited.jpg

Marie Cambot

Photo%20Laura%20Bencheikh_edited.jpg

Laura Bencheikh

Project Manager

Ils nous soutiennent

WILCO-LOGO_COULEURS-signature-FR-MEDIUM.

Région Ile de France

logo-CMJN-signature.jpg

Evry, Région Ile de France

MEDICEN.png

MEDICEN PARIS REGION

News

  • INNOVHEM is very pleased to announce the start of a preclinical Investigator Sponsored Trial with funding support by Jazz Pharmaceuticals, to support the development of new treatments for sickle cell disease

November, 27, 2020